The firm's oncology unit reported 16 percent growth in Q2, with nearly all oncology medicines reporting revenue growth in the ...
NEW YORK – Estrella Immunopharma's first trial of its CD19-directed autologous T-cell therapy for non-Hodgkin's lymphoma is progressing smoothly, the company said late last week, and it has moved on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results